374 related articles for article (PubMed ID: 18349829)
1. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
Varey AH; Rennel ES; Qiu Y; Bevan HS; Perrin RM; Raffy S; Dixon AR; Paraskeva C; Zaccheo O; Hassan AB; Harper SJ; Bates DO
Br J Cancer; 2008 Apr; 98(8):1366-79. PubMed ID: 18349829
[TBL] [Abstract][Full Text] [Related]
2. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
[TBL] [Abstract][Full Text] [Related]
3. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
Rennel ES; Varey AH; Churchill AJ; Wheatley ER; Stewart L; Mather S; Bates DO; Harper SJ
Br J Cancer; 2009 Oct; 101(7):1183-93. PubMed ID: 19707198
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
[TBL] [Abstract][Full Text] [Related]
5. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
7. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
[TBL] [Abstract][Full Text] [Related]
9. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
11. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
12. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
Perrin RM; Konopatskaya O; Qiu Y; Harper S; Bates DO; Churchill AJ
Diabetologia; 2005 Nov; 48(11):2422-7. PubMed ID: 16193288
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of VEGF induces cellular senescence in colorectal cancer cells.
Hasan MR; Ho SH; Owen DA; Tai IT
Int J Cancer; 2011 Nov; 129(9):2115-23. PubMed ID: 21618508
[TBL] [Abstract][Full Text] [Related]
15. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
16. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.
Calvani M; Trisciuoglio D; Bergamaschi C; Shoemaker RH; Melillo G
Cancer Res; 2008 Jan; 68(1):285-91. PubMed ID: 18172321
[TBL] [Abstract][Full Text] [Related]
17. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.
Watanabe M; Boyer JL; Crystal RG
Gene Ther; 2010 Aug; 17(8):1042-51. PubMed ID: 20596059
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
20. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
Fan F; Samuel S; Gaur P; Lu J; Dallas NA; Xia L; Bose D; Ramachandran V; Ellis LM
Br J Cancer; 2011 Apr; 104(8):1270-7. PubMed ID: 21407219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
